{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"NCT04736706","nct_id":"NCT04736706","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct04736706. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants will receive pembrolizumab 400 mg PLUS belzutifan 120 mg PLUS lenvatinib 20 mg. Pembrolizumab will be administered intravenously (IV) once every 6 weeks (Q6W) for up to 18 administrations (up to \\~2 years). Belzutifan and lenvatinib will be administered orally once daily (QD) until progressive disease or discontinuation.","label":"Pembrolizumab + Belzutifan + Lenvatinib","type":"EXPERIMENTAL"},{"description":"Participants will receive pembrolizumab/quavonlimab (co-formulation of pembrolizumab 400 mg and quavonlimab 25 mg) PLUS lenvatinib 20 mg. Pembrolizumab/quavonlimab will be administered IV Q6W for up to 18 administrations (up to \\~2 years). Lenvatinib will be administered orally QD until progressive disease or discontinuation.","label":"Pembrolizumab/Quavonlimab + Lenvatinib","type":"EXPERIMENTAL"},{"description":"Participants will receive pembrolizumab 400 mg PLUS lenvatinib 20 mg. Pembrolizumab will be administered IV Q6W for up to 18 administrations (up to \\~2 years). Lenvatinib will be administered orally QD until progressive disease or discontinuation.","label":"Pembrolizumab + Lenvatinib","type":"ACTIVE_COMPARATOR"}],"collaborators":["Eisai Inc."],"completion_date":{"date":"2027-04-22","type":"ESTIMATED"},"conditions":["Carcinoma, Renal Cell"],"enrollment":{"count":1688,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Pembrolizumab","otherNames":["MK-3475","KEYTRUDA®"],"type":"BIOLOGICAL"},{"name":"Belzutifan","otherNames":["MK-6482","PT2977","WELIREG™"],"type":"DRUG"},{"name":"Pembrolizumab/Quavonlimab","otherNames":["MK-1308A"],"type":"BIOLOGICAL"},{"name":"Lenvatinib","otherNames":["MK-7902","E7080","LENVIMA®"],"type":"DRUG"}],"last_update":"2026-10-02","lead_sponsor":"Merck Sharp & Dohme LLC","official_title":"An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or MK-1308A in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, as First-Line Treatment in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-02-04","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)","timeFrame":"Up to approximately 57 months"},{"measure":"Overall Survival (OS)","timeFrame":"Up to approximately 57 months"}],"references":[{"citation":"Choueiri TK, Powles T, Voss MH, Plimack ER, Gurney H, Song Y, Perini RF, Rodriguez-Lopez K, Rini BI. LITESPARK-012: pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab for advanced renal cell carcinoma. Future Oncol. 2023 Dec;19(40):2631-2640. doi: 10.2217/fon-2023-0283. Epub 2023 Oct 26.","pmid":"37882432","type":"DERIVED"},{"citation":"Ged Y, Markowski MC, Singla N, Rowe SP. The shifting treatment paradigm of metastatic renal cell carcinoma. Nat Rev Urol. 2022 Nov;19(11):631-632. doi: 10.1038/s41585-022-00651-9.","pmid":"36064785","type":"DERIVED"}],"start_date":{"date":"2021-04-14","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)","url":"https://clinicaltrials.gov/study/NCT04736706"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct04736706"}